DESIGN AND INVITRO CHARACTERIZATION OF RIVASTIGMINE TRANSDERMAL PATCHES

In present study transdermal drug delivery of Rivastigmine was developed to overcome the first pass metabolism and to reduce frequency of dosing compared to oral route. Matrix type of transdermal patches was developed by using polymers HPMCk4M and HPMCk15M.Transdermal patches were prepared by employing solvent casting method. Propylene glycol and Tween80 were selected as permeation enhancer and plasticizer. Formulations were prepared with the varying concentrations polymers ranging from F1-F12.Moisture content and Swelling study and all the results were found to be were found to be with in the pharmacopeial limits, invitro drug release studies by using dialysis membrane. Among all the 12 formulations F6 formulation which contain HPMC K4M 300mg and Eudragit L-100 60mg had shown 94% cumulative drug release with in 12 hours. And compared to HPMC K15M, HPMC K4M showed better drug release profile. For F6 formulation release kinetics were plotted and the Regression coefficient value was found to be high for Korsmeyer-peppas release model i.e., 0.9892. Key words: Rivastigmine, transdermal patches, HPMCk4M and HPMCk15M